公开(公告)号：WO2011100234A3

公开(公告)日：2012-03-15

申请号：PCT/US2011024030

申请日：2011-02-08

Applicant: STC UNM ,  CHACKERIAN BRYCE ,  PEABODY DAVID S

Inventor： CHACKERIAN BRYCE ,  PEABODY DAVID S

IPC: A61K38/17 ,  A61K38/16 ,  A61K47/30 ,  A61K47/48 ,  A61P31/00 ,  A61P31/12

CPC classification number: C07K14/005 ,  A61K39/12 ,  A61K47/48776 ,  A61K47/6901 ,  A61K2039/5258 ,  A61K2039/55566 ,  C12N7/00 ,  C12N2710/20023 ,  C12N2710/20034 ,  C12N2795/18123

Abstract: The invention provides immunotherapeutic and prophylactic bacteriophage viral-like particle (VLPs) which are useful in the treatment and prevention of human papillomavirus (HPV) infections and related disorders, including cervical cancer and persistent infections associated with HPV. Related compositions (e.g. vaccines), nucleic acid constructs, and therapeutic methods are also provided. VLPsand related ompositions of the invention induce high titer antibody responses against HPV L2 and protect against HPV challenge in vivo. VLPs, VLP-containing compositions, and therapeutic methods of the invention induce an immunogenic response against HPV infection, confer immunity against HPV infection, protect against HPV infection, and reduce the likelihood of infection by HPV infection.

Abstract translation: 本发明提供免疫治疗和预防性噬菌体病毒样颗粒（VLP），其可用于治疗和预防人乳头状瘤病毒（HPV）感染和相关疾病，包括宫颈癌和与HPV相关的持续感染。 还提供了相关组合物（例如疫苗），核酸构建体和治疗方法。 本发明的VLPs和相关症状诱导针对HPV L2的高滴度抗体应答并且在体内保护免受HPV挑战。 VLP，含VLP的组合物和本发明的治疗方法诱导针对HPV感染的免疫原性应答，赋予HPV感染免疫，防止HPV感染，并降低HPV感染感染的可能性。